Detalhe da pesquisa
1.
RIG-I Activation by a Designer Short RNA Ligand Protects Human Immune Cells against Dengue Virus Infection without Causing Cytotoxicity.
J Virol
; 93(14)2019 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31043531
2.
Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection.
J Virol
; 90(24): 11122-11131, 2016 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27707930
3.
Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines.
J Virol
; 88(13): 7276-85, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24741106
4.
Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques.
PLoS Pathog
; 9(8): e1003521, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23935499
5.
Plasmablasts generated during repeated dengue infection are virus glycoprotein-specific and bind to multiple virus serotypes.
J Immunol
; 189(12): 5877-85, 2012 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23152560
6.
Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement.
Antibodies (Basel)
; 12(2)2023 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37218902
7.
Diphtheria toxin activates ribotoxic stress and NLRP1 inflammasome-driven pyroptosis.
J Exp Med
; 220(10)2023 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37642997
8.
Immune cell phenotypes associated with disease severity and long-term neutralizing antibody titers after natural dengue virus infection.
Cell Rep Med
; 2(5): 100278, 2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34095880
9.
Altered monocyte response to the dengue virus in those with varying severity of past dengue infection.
Antiviral Res
; 169: 104554, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31288040
10.
Erratum: Publisher Correction: A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus.
NPJ Vaccines
; 3: 7, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29424838
11.
Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants.
PLoS One
; 13(1): e0189262, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29298302
12.
A potent neutralizing antibody with therapeutic potential against all four serotypes of dengue virus.
NPJ Vaccines
; 2: 2, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29263863
13.
Skin dendritic cell and T cell activation associated with dengue shock syndrome.
Sci Rep
; 7(1): 14224, 2017 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079750
14.
Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees.
Hum Vaccin Immunother
; 12(5): 1265-73, 2016 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-26889737
15.
Plasmablasts During Acute Dengue Infection Represent a Small Subset of a Broader Virus-specific Memory B Cell Pool.
EBioMedicine
; 12: 178-188, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27628668
16.
Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice.
Vaccine
; 33(12): 1474-82, 2015 Mar 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-25659270
17.
Dengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection.
Front Immunol
; 5: 388, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25177321
18.
Susceptibility and response of human blood monocyte subsets to primary dengue virus infection.
PLoS One
; 7(5): e36435, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22574162
19.
Dengue virus activates polyreactive, natural IgG B cells after primary and secondary infection.
PLoS One
; 6(12): e29430, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-22216280
20.
Biochemical and genetic characterization of dengue virus methyltransferase.
Virology
; 405(2): 568-78, 2010 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20655081